Corporate Update: Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.
Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. (0874.HK) closed the trading day unchanged, recording a flat 0 % move over the 24‑hour period ending at 05:52 AM Central Europe on Wednesday 21 October. The share remains priced at approximately HKD 13.10 on the Hong Kong Stock Exchange, with a current free float of 219.9 million shares. Its market capitalisation stands at HKD 21.6 billion, while intraday trading volume has been modest at about HKD 10.1 million.
Market Context
Since the close of last month, the stock has risen 1.45 %. The 200‑day simple moving average, a key technical indicator, sits at HKD 16.26, indicating a medium‑term support level. The 52‑week high of HKD 20.40 was reached on 14 November 2025, and the low of HKD 12.74 occurred on 25 September 2026. These figures suggest the share is currently trading near the lower bound of its recent range, hinting at potential upside if a trend reversal occurs.
Comparative Performance
In the same 24‑hour window, other peer stocks have shown varied activity:
| Ticker | 24‑hr change | Current price | Market cap | PE (if available) |
|---|---|---|---|---|
| 688475.SS (Hangzhou Ezviz Network) | 0 % | CNY 28.01 | CNY 21.6 bn | – |
| 2768.HK (Qingdao Gon) | +3.05 % | HKD 33.20 | HKD 25.7 bn | 24.93 |
| 2228.HK (Xtalpi) | +0.51 % | HKD 6.16 | HKD 25.5 bn | – |
| 300199.SZ (Hybio Pharmaceutical Ltd.) | 0 % | CNY 27.21 | CNY 22 bn | 184.82 |
| 002262.SZ (Jiangsu Ninhua Pharmaceutical) | 0 % | CNY 22.01 | CNY 22 bn | 19.93 |
The lack of movement for Guangzhou Baiyunshan Pharmaceutical is notable against the backdrop of a modest 3 % rally for Qingdao Gon and the high valuation of Hybio Pharmaceutical. This could indicate a consolidation phase for the company as it positions itself for future growth initiatives.
Strategic Outlook
Guangzhou Baiyunshan Pharmaceutical’s core competencies lie in the manufacturing and distribution of Chinese patent medicines, as well as the import‑export of both Western and Chinese pharmaceutical products. Since its IPO on 30 October 1997, the company has steadily expanded its product portfolio and market reach, leveraging its established retail and wholesale networks across China.
Recent market data suggest that the company remains undervalued relative to its 200‑day moving average, providing a potential entry point for long‑term investors. Moreover, the flat 24‑hour trading activity may reflect a period of strategic reassessment rather than market sentiment. Analysts anticipate that upcoming product launches and potential regulatory approvals could serve as catalysts for a renewed upward trajectory.
For further details on Guangzhou Baiyunshan Pharmaceutical’s operations, product lines, and corporate governance, visit the official website at www.gpc.com.cn .
